Red pills in blister packs. (Photo: Oksana Kazykina/AdobeStock)

Despite efforts by the FDA to ensure essential drug supplies, the number of drug shortages has stubbornly plateaued since 2018. Supply chain shortages during the COVID-19 pandemic have highlighted the sometimes-precarious situation of essential drug manufacturing, and recent disruptions in China and Russia have only further tightened the market, according to FiercePharma. Now, the FDA is working to prevent future supply chain shortages by requiring certain manufacturers to prepare risk management plans. In a draft guidance released May 19th, the agency announced that its new rules would affect manufacturers of drugs that are used to treat rare diseases, can be used during a public health crisis, and drugs which lack alternatives.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.